Sarcoidosis is a chronic inflammatory disease in which the immune system forms tiny clusters of inflamed cells, called granulomas, in one or more organs. The lungs are affected in about 90% of cases, but sarcoidosis can also target the skin, eyes, heart, brain, and virtually any other part of the body. Some people recover without treatment, while others develop persistent disease that requires long-term medication.
What Happens Inside the Body
In sarcoidosis, the immune system overreacts to an unknown trigger. White blood cells, primarily a type called CD4+ T cells, become overactive and flood into tissues. Once there, they recruit macrophages, the immune cells responsible for engulfing foreign material. Instead of resolving normally, these macrophages transform into specialized structures called epithelioid cells and sometimes fuse into giant cells with multiple nuclei. The result is a granuloma: a tightly organized ball of immune cells surrounded by a ring of lymphocytes.
These granulomas are not cancerous, but they cause problems by physically crowding out normal tissue and driving ongoing inflammation. A signaling pathway inside macrophages stays chronically switched on, which keeps granulomas from dissolving the way they would after a typical infection clears. The level of this signaling activity in lung tissue correlates with progressive disease and new granuloma formation. A specific subset of immune cells called Th17.1 cells, which pump out high levels of the inflammatory protein interferon-gamma, appears to be a key driver of the process.
Who Gets Sarcoidosis
Sarcoidosis can develop at any age but most commonly appears between ages 20 and 40. It affects people of every background, though rates vary dramatically by race. In the United States, Black individuals have roughly double the incidence of white individuals (17.8 versus 8.1 per 100,000) and nearly triple the prevalence (141.4 versus 49.8 per 100,000). Black women carry the highest burden, with a prevalence of 178.5 per 100,000. The disease also tends to be more severe and less likely to resolve on its own in Black patients.
Suspected Causes and Triggers
No single cause of sarcoidosis has been identified. The leading theory is that genetically susceptible people develop the disease after inhaling or encountering a triggering substance. Several types of triggers are under investigation. On the infectious side, certain bacteria, including mycobacteria (relatives of the tuberculosis organism) and a common skin bacterium called Propionibacterium acnes, have been found in granulomas. On the environmental side, exposure to organic dusts, mold, musty workplace odors, insecticides, and products of combustion have all been linked to increased risk. Some studies note seasonal patterns in diagnosis, suggesting airborne bioaerosols that peak in spring or summer could play a role.
Genetics matter too. Variations in HLA genes, which control how the immune system recognizes foreign material, have been associated with developing sarcoidosis, being protected from it, or developing specific patterns of organ involvement. The interplay between a person’s HLA type, the triggering substance, and the T cell receptors that respond to it appears central to whether the disease takes hold.
Lung Involvement and Staging
Because the lungs are involved in the vast majority of cases, chest imaging plays a central role in evaluation. Doctors classify pulmonary sarcoidosis into five stages based on chest X-ray findings:
- Stage 0: Normal chest X-ray, no visible lung disease
- Stage 1: Enlarged lymph nodes near the lungs (hilar lymphadenopathy) but no lung tissue changes
- Stage 2: Enlarged lymph nodes plus abnormalities in the lung tissue itself
- Stage 3: Lung tissue abnormalities without enlarged lymph nodes
- Stage 4: Permanent scarring (fibrosis) with loss of lung volume
These stages are used to estimate prognosis, not to describe a disease that inevitably worsens step by step. Most patients never progress beyond stage 1 or 2. Stage 1 has the highest likelihood of spontaneous remission, while stage 4 represents irreversible damage. Stages 2 and 3 carry a similar outlook to each other.
Symptoms Beyond the Lungs
Sarcoidosis is often called “the great imitator” because it can mimic so many other conditions. Lung symptoms like a persistent dry cough, shortness of breath, and chest discomfort are the most common complaints. But the disease reaches well beyond the chest.
Skin involvement produces several recognizable patterns. Erythema nodosum, tender reddish bumps typically on the shins, is a common early sign that often accompanies a mild, self-limited course. Lupus pernio, a chronic condition causing purplish, hardened patches on the nose, cheeks, and ears, signals more persistent disease. Eye inflammation (uveitis) can cause redness, pain, blurred vision, and sensitivity to light. Without treatment, it can lead to permanent vision loss.
Cardiac Sarcoidosis
When granulomas form in the heart, they tend to cluster in the wall between the heart’s lower chambers. This location makes electrical conduction problems the hallmark of cardiac sarcoidosis. Palpitations, dizziness, and fainting are the most common symptoms. In one study, a type of heart block was the first sign of cardiac involvement in more than 40% of patients, with abnormal fast heart rhythms accounting for another 28%. These electrical disturbances can be life-threatening, making cardiac sarcoidosis one of the most serious forms of the disease.
Neurosarcoidosis
Between 5% and 10% of sarcoidosis patients develop neurological complications. The facial nerve is the most commonly affected, causing weakness or paralysis on one side of the face that can look identical to Bell’s palsy or Lyme disease. Other neurological symptoms include headaches, vision changes from optic nerve involvement, hormonal disruptions when the hypothalamus is affected, and numbness or weakness from spinal cord inflammation. A rare presentation called Heerfordt syndrome combines facial nerve palsy with swollen salivary glands, eye inflammation, and fever. Facial palsy from sarcoidosis typically improves over four to six weeks.
How Sarcoidosis Is Diagnosed
There is no single blood test or scan that confirms sarcoidosis. Diagnosis rests on three pillars: symptoms and imaging that fit the pattern, a tissue biopsy showing the characteristic granulomas, and ruling out other diseases that can look similar, including tuberculosis, fungal infections, and certain cancers.
Doctors aim to biopsy whichever affected site is safest and easiest to reach. Skin lesions, superficial lymph nodes, and muscle are all accessible options. When the lungs are the primary target, bronchoscopy with ultrasound-guided needle sampling of lymph nodes near the airways has become the go-to approach, with diagnostic accuracy of 80% to 90% in early-stage disease. For later stages without enlarged lymph nodes, transbronchial lung biopsies succeed in 50% to 75% of attempts. About 23% of patients are diagnosed based on clinical and imaging findings alone, without a biopsy.
PET/CT scanning, which highlights areas of active inflammation throughout the body, is more sensitive than older nuclear medicine scans for detecting sarcoidosis lesions. It cannot confirm the diagnosis by itself since cancers and infections light up the same way, but it is particularly useful for spotting disease in hard-to-biopsy locations like the heart, brain, or bone, and for guiding where to take a tissue sample.
Treatment
Not everyone with sarcoidosis needs treatment. The decision depends on which organs are involved, how severe the symptoms are, and whether the disease appears to be progressing. Mild cases, especially stage 1 lung disease, are often monitored with periodic imaging and lung function tests.
When treatment is needed, corticosteroids are the first choice. Guidelines recommend a starting dose equivalent to 20 to 40 mg of prednisone daily, followed by a slow taper over months. Corticosteroids are effective at suppressing granuloma formation, but long-term use carries well-known side effects including weight gain, bone thinning, elevated blood sugar, and mood changes.
To reduce dependence on steroids, doctors often add a second-line medication. Methotrexate is the most commonly used, along with mycophenolate, leflunomide, and azathioprine. These drugs dampen the immune response through different mechanisms and allow steroid doses to be lowered, though they come with their own monitoring requirements and are not always effective or well tolerated.
For patients whose disease does not respond to steroids and a second-line agent, biologic medications that block the inflammatory protein TNF-alpha, particularly infliximab and adalimumab, are considered third-line options. Newer targeted therapies, including JAK inhibitors like tofacitinib, have shown promise in small studies, especially for skin disease. In England, infliximab has been approved through routine commissioning specifically for refractory sarcoidosis.
Long-Term Outlook
Sarcoidosis is unpredictable. In one follow-up study, about 20% of patients experienced complete spontaneous remission without any treatment. On the other end of the spectrum, roughly 18% developed chronic disease requiring ongoing medication that could not be discontinued. The majority fell somewhere in between, with disease that responded to treatment and eventually stabilized or resolved.
Stage at diagnosis is one of the strongest predictors of outcome. Stage 1 disease has the best chance of clearing on its own. Stage 4, with established lung scarring, represents permanent damage, though inflammation can still be managed to prevent further decline. Cardiac and neurological involvement generally require more aggressive treatment and closer monitoring. Black patients, on average, face a higher risk of chronic progressive disease, which may reflect a combination of genetic factors, environmental exposures, and disparities in access to specialized care.